Year Interim Data From News Today : Breaking News, Live Updates & Top Stories | Vimarsana

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage to the nervous system, new research demonstrates.
“We are encouraged by these new analyses showing that early treatment with Ocrevus may significantly control disease progression in both relapsing-remitting MS and in primary progressive MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech (a member of the Roche Group), which makes Ocrevus, said in a press release. ....

United States , New York , Levi Garraway , Timothy Vollmer , Gabriel Pardo , Robert Zivadinov , University Of Lisbon , Biomedical Sciences , Oklahoma Medical Research Foundation , University Of Colorado , Society Of America , University Of Pittsburgh , American Academy Of Neurology , Roche Group , University At Buffalo , Multiple Sclerosis News Todayteam , American Academy , Diagnosed Early Stage , Disability Progression , Serum Neurofilament , Year Interim Data From , Ocrelizumab Phase , Expanded Disability Status Scale , Cerebrospinal Fluid , Primary Progressive Multiple Sclerosis , Disease Modifying Therapies ,